, Volume 47, Issue 4, pp 686–694 | Cite as

Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes

  • N. Marzo
  • C. Mora
  • M. E. Fabregat
  • J. Martín
  • E. F. Usac
  • C. Franco
  • M. Barbacid
  • R. Gomis



Cyclin-dependent kinase 4 (Cdk4) is crucial for beta cell development. A mutation in the gene encoding for Cdk4, Cdk4R24C, causes this kinase to be insensitive to INK4 cell cycle inhibitors and induces beta cell hyperplasia in Cdk4R24C knockin mice. We aimed to determine whether this Cdk4R24C mutation also affects proper islet function, and whether it promotes proliferation in human islets lentivirally transduced with Cdk4R24C cDNA.


Our study was conducted on wild-type and Cdk4R24C knockin mice. Pancreases were morphometrically analysed. Intraperitoneal glucose tolerance tests and intravenous insulin tolerance tests were performed on wild-type and Cdk4R24C mice. We also did in vitro islet perifusion studies and islet metabolic labelling analysis. Human islets were transduced with Cdk4R24C cDNA.


Pancreatic islets from Cdk4R24C knockin mice exhibit a larger insulin-producing beta cell area and a higher insulin content than islets from wild-type littermates. Insulin secretion in response to glucose is faster and reaches a higher peak in Cdk4R24C mice without leading to hypoglycaemia. Conversion of proinsulin into insulin and its intermediates is similar in Cdk4R24C and wild-type mice. Glucose utilisation and oxidation measured per islet were similar in both experimental groups. Insulin secretion was faster and enhanced in Cdk4R24C islets perifused with 16.7 mmol/l glucose, with slower decay kinetics when glucose returned to 2.8 mmol/l. Moreover, human islets expressing Cdk4R24C cDNA exhibited higher beta cell proliferation.


Despite their hyperplastic growth, Cdk4R24C insulin-producing islet cells behave like differentiated beta cells with regard to insulin production, insulin secretion in response to glucose, and islet glucose metabolism. Therefore Cdk4 could possibly be used to engineer a source of beta cell mass for islet transplantation.


Beta cell replication Cdk4R24C Cyclin-dependent kinase 4 (mutation R24C) Insulin secretion Normoglycaemia 



cyclin-dependent kinase 4




green fluorescence protein


intraperitoneal glucose tolerance test


intravenous insulin tolerance test




Loss of beta cell mass is due to the negative balance between beta cell recovery and destruction in Type 1 diabetes (recurrent destruction due to autoimmunity) and in Type 2 diabetes (beta cell death unrelated to an autoimmune process). Beta cell mass increases by differentiation of precursor cells or by replication of pre-existing islet cells [1]. The increase in beta cell mass is determined by the number of cells entering the cell cycle (G1 phase) rather than by changes in the rate of cell cycle progression [2].

The transition between cell cycle phases is controlled by critical checkpoints, in which cyclins and cyclin-dependent kinases play an important role. Four main types of cyclin are involved in cell cycle control: A, B, D and E [3]. D cyclins (D1, D2, D3) facilitate the entry of cells into the cell cycle (G1 phase) in response to growth-stimulating factors, by binding and activating the specific protein-kinases cyclin-dependent kinase 4 (Cdk4) and cyclin-dependent kinase 6 [4]. The activity of the Cdk-cyclin complex can be inhibited by phosphorylation or through binding to Cdk inhibitors such as the Ink4 and CIP/KIP families [5]. By binding to cyclin D1, moreover, Cdk4 mediates post-natal beta cell proliferation [2, 6]. However, Cdk4 deficiency has been shown to cause severe diabetes mellitus associated with pancreatic islet degeneration [4, 7]. Abnormal expression of the Cdk inhibitor p21 is associated with impaired beta cell proliferation in pancreatic islets, and this defect in beta cell proliferation is seen in some types of diabetes [8].

It has recently been shown that Cdk4R24C, the hyperactive mutated form of Cdk4 that prevents the binding of Cdk4 to INK4 [9], causes pancreatic islet hyperplasia specific for beta cells [4]. In the present study we aimed to characterise the functionality of pancreatic islets in response to glucose in Cdk4R24C mice, and to causally relate Cdk4 hyperactivation to increased beta cell replication in response to glucose in human islets.

Materials and methods

Experimental mice

Cdk4R24C knockin mice (Panlab, Cornellà, Spain) have been previously described [4] in the mixed CD1/129Sv genetic background. Unless otherwise stated, 2-month old homozygous Cdk4R24C/R24C male or female mice were studied, and CD1/129Sv wild-type mice were used as a control group. The experimental mice were housed under a 12-h dark/light cycle with free access to a standard rodent diet (Panlab). All animal experimental procedures were reviewed previously and approved by the Institutional Ethical Committee of the University of Barcelona.

Morphometric studies

Mice were killed by cervical dislocation. Pancreases were then removed, fixed in 4% paraformaldehyde and dehydrated in 30% sucrose. For insulin immunostaining frozen sections were stained with an anti-insulin antibody (ICN, Costa Mesa, Calif., USA) detected by a peroxidated secondary antibody (Sigma-Aldrich Química, Madrid, Spain). AEC chromogen was used as peroxidase substrate. Toluidine blue was used for islet counter-staining. The beta cell area was quantified in a blinded fashion using optic microscopy and MicroImage software (Hamburg, Germany).

Islet insulin content

To obtain total islet protein, islets were isolated by collagenase digestion of total pancreases, using a modified version of a previously described procedure [10]. They were then immersed in an acid–alcohol solution, sonicated and left overnight at 4 °C. After centrifugation and protein purification from the supernatant, insulin content was determined by RIA (Insulin-CT, CIS bio International, Cedex, France). The results are expressed as insulin content per 10 islets.

Proinsulin biosynthesis and conversion

Isolated islets (60 islets per experimental condition) from wild-type and Cdk4R24C mice were incubated in 16.7 mmol/l glucose while being pulsed for 10 min with 35S-methionine (Amersham, Freiburg, Germany) and chased for 30, 60, 180 and 300 min respectively. Islets were lysed by sonication, pre-incubated for 1 h in Cowan solution (Sigma-Aldrich Química) at room temperature, and at 4 °C overnight with IMAD B37 (insulin immunoabsorbent) kindly provided by J. Hutton (Department of Clinical Biochemistry, University of Cambridge, UK). After washing with Low Background Solution (25 mmol/l Na2B4O7, 1 mmol/l EDTA, 0.1% NaN3, 1% Tween-20, 6% BSA; 3 washes), Lysis Buffer (50 mmol/l TRIS pH 7.5, 150 mmol/l NaCl, 1% Triton X-100, 0.1% SDS, 5 mmol/l EDTA, 1% deoxycholic sodium salt; 2 washes), and water (1 wash), insulin and proinsulin were eluted with 25% acetic acid and dried overnight using speed vacuum at room temperature. Samples were resuspended in loading buffer (9 mol/l urea, 0.25 mol/l TRIS pH 8.3) and separated in an alkaline urea gel. Once electrophoresis had finished, the gel was fluorographed using PPO/glacial acetic acid and then dried, and exposed. Autoradiographs were quantified using densitometric analysis and normalised per total cpm incorporated.

Results were normalised according to the amount of radiolabelled protein. To quantify the insulin released, the supernatant of the incubation with 35S-methionine was processed in the same ways as the pellets containing the islets.

Insulin secretion

The protocol was based on a modified version of one already described [11]. Isolated islets were perifused (33 islets per perifusion chamber) with 2.8 mmol/l glucose for 15 min. At this time point the glucose concentration was increased to 16.7 mmol/l for 40 min and then returned to 2.8 mmol/l. Supernatant was retrieved at various time points and insulin secretion determined by RIA.

Metabolic parameters

Blood glucose was measured using an automatic glucose monitoring device (Glucometer elite; Química Farmacéutica Bayer, Barcelona, Spain). Insulinaemia was measured by RIA. Two-month old male and female mice which had fasted for three hours were used to determine insulinaemia.

Intraperitoneal glucose tolerance test

Before the intraperitoneal glucose tolerance test (IGTT) mice were anaesthesised using sodium pentobarbital (60 mg/kg). After fasting for 16 h, they received an intraperitoneal injection of 150 mg glucose per kg body weight. Glycaemia and insulinaemia were measured at 0, 15, 30, 60 and 120 min after the injection. Insulinaemia was determined using an ultrasensitive rat insulin ELISA kit (Mercordia, Upsala, Sweden). Glycaemia was determined as previously described.

Intravenous insulin tolerance test

Before the intravenous insulin tolerance test (IITT) mice were anaesthesised using sodium pentobarbital (60 mg/kg). After 16 h of fasting, 1 IU insulin per kg body weight (Regular Humulin; Lilly, Indianapolis, Ind., USA) was injected into the tail vein. Insulinaemia was measured at 0 min, and glycaemia at 0, 15, 30, 45 and 60 min after the injection. Insulinaemia and glycaemia were determined as previously described.

Glucose oxidation and utilisation

Groups of 15 islets per condition were incubated at 37 °C for 120 min in bicarbonate buffered medium (40 µl) (460 mmol/l NaCl, 96 mmol/l NaHCO3, 20 mmol/l KCl, 4 mmol/l MgCl2, 4 mmol/l CaCl2, 16.7 mmol/l glucose) containing D-(5-3H) glucose and D-(U-14C) glucose. Incubation was stopped by the addition of citrate-NaOH buffer (400 mmol/l, pH 4.9) containing antimycin-A (10 µmol/l) (Sigma, Madrid, Spain), rotenone (10 µmol/l) (Sigma) and potassium cyanide (5 mmol/l). Glucose oxidation was measured by the generation of hyamine hydroxide-trapped 14CO2 (Carlo Erba, Milan, Italy) after 60 min incubation at room temperature. Glucose utilisation was determined by measuring the amount of 3H2O in 0.5 ml HCl (0.1 mol/l) after 20 h incubation at room temperature. The islet size was homogeneously distributed among both experimental groups, so both groups had the same number of large, average-sized and small islets.

Lentiviral vector construction and human islet infection

The non-replicative lentivirus particles were produced as previously described [12]. Briefly, three plasmidic constructions were co-transfected in the 293T cell line by the CaCl2 precipitation method in order to obtain viral particles as follows: (i) the vector (env-coding plasmid) required for the formation of the Vesicular Stomatitis Virus capsid; (ii) the pCMVΔR9, non-replicative, HIV-like vector encoding for the gag and pol lentiviral proteins required to encapsulate the viral particles into the Vesicular Stomatitis Virus capsid; and (iii) the third vector encoding the cDNA of interest, i.e. Cdk4/R24C, β-galactosidase (LacZ) or green fluorescence protein (GFP), under the cytomegalovirus (CMV) promoter (pHR′-CMV). The pHR′-CMV-LacZ vector, env-coding vector and PCMVΔR9 plasmid were provided by B. Thorens (Institute of Pharmacology, University of Lausanne, Switzerland).

Human islets were obtained by collagenase digestion from a deceased and previously healthy donor, with previous written consent from the donor or close relatives, following our established protocol [13] and cultured for 24 h in RPMI 1640 medium containing 11.1 mmol/l glucose (BioWhittaker, Verviers, Belgium), glutamine, penicillin-streptomycin (BioWhittaker) and 10% FCS. The islets were then cultured for 24 h in RPMI 1640 supplemented with either 5.5 mmol/l or 11.1 mmol/l glucose. Next islets were partially disaggregated in EH Ca++ Fre EGTA solution (30 mmol/l NaCl, 5.4 mmol/l KCl, 0.8 mmol/l MgSO4. 7H2O, 8.7 mmol/l NaH2PO4, 14 mmol/l NaHCO3, 1.6 mmol/l HEPES, 1 mmol/l EGTA) and infected for 4 h with lentiviral particles (20 IU/beta cell). After this, islets were cultured in the corresponding medium (5.5 mmol/l or 11.1 mmol/l glucose) for 2 days, and 12.5 mmol/l hydroxyurea medium was added for 24 h. Islets were then washed in Hanks’ Balanced Salt Solution and cultured in 5.5 mmol/l or 11.1 mmol/l glucose for 3 h, after which tritiated thymidine (3H-thymidine, 370 kBq/ml) was added for 1 h. Next islets were counted and the same number of islets pelleted for each experimental condition. To quantify proliferation, beta cell radiation was measured.

Statistical analysis

All values are expressed as means ± SEM. Statistical analysis was by Student’s t test or ANOVA, depending on the case. Findings were considered to be statistically significant at a p value (*p) of less than 0.05 or at a p value (**p) of less than 0.005. The p values are given in the figure legends.


Higher beta cell mass and insulin content in Cdk4R24C knockin mice

As Cdk4 is essential for attaining the steady-state beta cell mass that allows stable normoglycaemia, very probably by inducing beta cell proliferation, we characterised the insulin-producing beta cell mass and insulin content per islet in Cdk4R24C knockin mice and wild-type controls. Whole pancreases from 2-month old Cdk4R24C knockin mice or wild-type littermates were immunostained for insulin. The former exhibited a higher insulin-producing beta cell area per islet, approximately twice that of wild-type littermates (R24C knockin mice: 47200±9135 µm2, n=180 islets from six mice; wild-type mice: 24800±2356 µm2, n=180 islets from six mice) (Fig. 1a). Our observation of a significant increase in beta cell mass per islet when CDK4 is hyperactive explains the pancreatic islet hyperplasia observed in Cdk4R24C knockin mice [4]. Supporting these findings, the insulin content was also almost twice as high in islets from Cdk4R24C knockin mice (990 ng insulin/10 islets) as in wild-type mice (556 ng insulin/10 islets) (Fig. 1b). Interestingly, neither glycaemia nor insulinaemia differed significantly between the two groups at the two ages tested, i.e. 2 months (young mice) (Fig. 2), and 12 months (mature mice) (Fig. 3). At maturity, moreover, Cdk4R24C knockin mice had a normal response to exogenous insulin (similar to that in wild-type littermates) (Fig. 3c).
Fig. 1

Insulin immunostaining of islets (a) from wild-type (left) and Cdk4R24C mice (right). Beta cell surface per islet was quantified. Insulin content (b) from wild-type (WT) and Cdk4R24C (R24C) islets. Results are given as means ± SEM of blinded observations on 6 different mice per experimental group (30 islets per mouse). *p<0.05

Fig. 2

Fasting blood glucose (a) and plasma insulin concentration (b) in 2-month old wild-type (WT) and Cdk4R24C (R24C) mice. Results are given as means ± SEM. WT: n=7; R24C: n=11

Fig. 3

Fasting blood glucose (a) and plasma insulin concentration (b) in 12-month old wild-type (WT) and Cdk4R24C (R24C) mice. Results are given as means ± SEM using a minimum of 3 female mice for fasting insulinaemia and a minimum of 6 mice (male and female) for glycaemia measurements. c. Intravenous insulin tolerance test. Mice (male and female) were intravenously injected 1 IU insulin/kg body weight and glycaemia values were determined at different time points. Results are given as means ± SEM. White squares: WT mice (n=6); black circles: R24C mice (n=6)

Proinsulin biosynthesis and conversion in Cdk4R24C islets unaltered

To investigate whether proinsulin was correctly processed in Cdk4R24C islets, we performed pulse-chase experiments on islets from wild-type and Cdk4R24C mice and determined proinsulin, intermediate molecules and insulin by fluorography (Fig. 4a). The ratio proinsulin : insulin plus intermediates was quantified densitometrically (Fig. 4b). Neither qualitative nor quantitative differences between Cdk4R24C and wild-type islets were observed in the processing of proinsulin into its intermediates and insulin (Fig. 4), suggesting that the increased insulin produced in Cdk4R24C islets is metabolically active. As Cdk4R24C mice were normoglycaemic and their fasting insulinaemia was similar to that of wild-type mice (Fig. 2, Fig. 3), our results show that insulin secretion rather than insulin production could be the key control point in preventing hypoglycaemia in Cdk4R24C knockin mice.
Fig. 4

Proinsulin biosynthesis and conversion. a Islets from wild-type (WT, left) and CdkR24C (R24C, right) mice were pulse-labelled with S35-Methionine and chased at different times. Immunoprecipitation of insulin + intermediates (INS + INT) and proinsulin (PROINS) is shown. b Proinsulin/insulin + intermediates levels during chase. Values are expressed as means ± SEM of 3 independent experiments. White bars: WT; black bars: R24C

Cdk4R24C knockin mice have a more tightly controlled normoglycaemia due to increased insulinaemia in response to glucose stimulus

We did IGTTs on Cdk4R24C knockin mice and wild-type littermates to determine whether the physiological triggering of insulin secretion was abnormal in the former. Glycaemia and insulinaemia were measured in parallel from blood samples taken before (0 min) and at different time points (15, 30, 60 and 120 min) after an intraperitoneal injection of glucose. The glycaemic peak 30 min after the glucose injection was lower in Cdk4R24C knockin mice (8.7 mmol/l) than that in wild-type controls (11.15 mmol/l), as was glycaemia at 60 min, by which time Cdk4R24C knockin mice were already normoglycaemic (5.8 mmol/l vs 9.4 mmol/l in wild-type mice) (Fig. 5a). The wild-type group did not reach normoglycaemia until 120 min. The results for insulinaemia mirrored the glycaemia values (Fig. 5b), with Cdk4R24C knockin mice reaching a significantly higher peak of insulinaemia (1.77 ng insulin/ml) 15 min after the glucose injection, while the wild-type group was slower to peak (at 30 min). This peak was also significantly lower than the 30-min value for Cdk4R24C knockin mice (1.24 vs 1.43 ng/ml respectively). Both groups had returned to basal insulin levels by 120 min after the glucose injection. These results suggest that Cdk4R24C knockin mice have more efficient glucose clearance because their pancreatic islets contain more insulin ready for release upon glucose stimulation.
Fig. 5

Intraperitoneal glucose tolerance test on wild-type (WT) and CdkR24C (R24C) mice. Time course of blood glucose (a) and plasma insulin (b) after a glucose injection at 0 min. Results are given as means ± SEM. Rhomb: WT (n=9); square: R24C (n=7). *p<0.05, **p<0.005

Glucose utilisation and oxidation in Cdk4R24C knockin mice

As glucose uptake, phosphorylation and ulterior metabolism in pancreatic islets trigger insulin secretion in response to blood glucose levels, we ascertained whether glucose utilisation in the glycolytic pathway and its oxidation in the Krebs cycle are altered in Cdk4R24C knockin islets. To obtain pancreatic islets, we killed the Cdk4R24C knockin and wild-type mice. We then incubated the islets ex vivo at 37 °C and two different glucose concentrations (5.5 and 16.7 mmol/l) for 2 h. This was done in the presence of either D-(5-3H) glucose (glucose utilisation) or D-(U-14C) glucose (glucose oxidation). After incubation was stopped, we measured either 3H2O (utilisation) or 14CO2 (oxidation). No significant differences between the experimental groups were found (Fig. 6), when normalised per islet at the two concentrations tested. These results suggest that the physiological and tuned functionality of Cdk4R24C islets is comparable to that of wild-type counterparts at the ages analysed.
Fig. 6

Glucose metabolism in isolated islets of wild-type (WT) and Cdk4R24C (R24C) mice. a Glucose utilisation. Results are given as means ± SEM of 8 observations from 2 separate experiments. b Glucose oxidation. Results are given as means ± SEM of 12 observations from 3 separate experiments. White bars: WT; black bars: R24C

Ex vivo perifused Cdk4R24C islets exhibit higher and more lasting insulin secretion in response to high glucose concentrations than wild-type counterparts

Although the IGTT test revealed the close control of insulin release in Cdk4R24C knockin mice, it was an in vivo observation, and therefore did not discriminate between the intervention of various organs in glucose and insulin clearance from the blood. We therefore performed islet perifusion using isolated islets in the presence of a high glucose concentration and measuring insulin secretion to the medium at different time points. Aliquots were withdrawn from the incubation media (Fig. 7) at the time points indicated and insulin content assayed by RIA. Upon stimulation with the high-glucose solution, wild-type islets reached an insulin release peak at about 32 min, returning almost to basal levels of insulin secretion after changing to the low-glucose medium (55 min). Interestingly, the amplitude of the insulin secretion peak was greater in the Cdk4R24C islets, in agreement with the IGTT test results. It also lasted longer, just starting to return to basal levels at 55 min (the end of the low-glucose medium incubation) (Fig. 7). This is surprising, for despite the ex vivo insulin secretion of Cdk4R24C islets in response to glucose, living Cdk4R24C knockin mice do not show fasting hypoglycaemia or hyperinsulinaemia. Moreover, in the IGTT test, using a single glucose injection, the rate of recovery of basal insulinaemia in Cdk4R24C and wild-type mice was similar.
Fig. 7

Insulin secretion from perifused islets. Data are from 2 independent experiments with islets from wild-type (rhomb) or CdkR24C (square) mice. Results are given as means ± SEM of 6 independent observations from 2 different experiments

Cdk4R24C confers higher proliferative capability on Cdk4R24C-expressing human islets

The R24C mutation in Cdk4 could be used to generate an immortalised human beta cell line for in vitro studies. We therefore wondered whether Cdk4 activation is sufficient on its own to promote human beta cell proliferation, thus providing a potentially unlimited source of physiologically functional human beta cells for use in islet transplantation. To answer this question, we infected human islets with non-replicative lentiviral particles expressing either Cdk4R24C or LacZ as control, and cultured them in 5.5 or 11.1 mmol/l glucose. The efficiency of infection was monitored by infecting several islets with GFP-expressing lentiviral vector (after every efficient infection high levels of GFP protein could be observed in the islet core). Measurement of 3H-thymidine incorporation showed that Cdk4R24C-infected islets proliferated at higher rates (61.23 cpm) than LacZ-infected controls (41.8 cpm) at 11.1 mmol glucose, and that proliferation increased significantly when the glucose concentration was raised from 5.5 mmol/l to 11.1 mmol/l in Cdk4R24C-infected islets (40.73 vs 61.23 cpm) (Fig. 8). This result suggests that Cdk4-induced proliferation in beta cells is related to changes in exogenous glucose concentration, which is a powerful physiological stimulus.
Fig. 8

Proliferation of human islets infected with lentiviral vectors carrying Cdk4R24C (R24C, black bars) cDNA or β-galactosidase (LacZ, white bars) as controls. Analysis was by ANOVA. Results are normalised per islet and expressed as means ± SEM. This figure is representative of 3 independent experiments. *p<0.05


The transplantation of beta cells is vital for restoring normoglycaemia in Type 1 diabetic patients. Compared with whole pancreas transplantation, beta cell transplantation has much lower levels of associated morbidity and mortality [14]. Its success and feasibility, however, are severely limited by the relatively high number of viable human islets required (12000 islet equivalent/kg body weight) in each graft procedure [15]. Islet yield after the isolation procedure is not totally efficient and varies between laboratories, with two to three donor pancreases needed per Type 1 diabetic recipient to re-establish normoglycaemia [16]. For these compelling reasons, several groups have attempted to modify the number of islets transplanted by making them more resistant to cell death or inducing them to replicate, either in vitro, or after transplantation [12, 17, 18]. One approach involves the conditional transformation of a mouse beta cell line using the SV40 T antigen under the control of tetracycline-responsive element [19].

The present study describes a new potential target for inducing beta cell replication, namely Cdk4, which is specifically involved in post-natal beta cell proliferation. Hyperactivity of Cdk4, caused by the R24C mutation that inhibits the binding of INK4 inhibitors to Cdk4, promotes specific beta cell hyperplasia. The main function of the Cdk4/cyclin complexes could be to phosphorylate and inactivate the retinoblastoma (Rb) protein [20]. INK4 inhibitors associate with Cdk4 monomers in vivo [21] and prevent cyclin D1 binding to Cdk4, causing cell cycle arrest. The abrogation of INK4 inhibitors binding to Cdk4 promotes the entrance of the beta cell into the cycle, and an increase in beta cell mass. Against this background, we have characterised the Cdk4R24C phenotype physiologically and biochemically to ascertain whether insulin secretion and glucose metabolism remain unaltered. In addition, the Cdk4 protein is naturally expressed in beta cells and not a non-self antigen expressed ectopically to induce replication [19]. As beta cell mass augmentation depends on cells likely to enter the G1 phase, and as the beta cell area at the age of 2 months was two times greater than in wild-type mice, we propose (and there is experimental evidence 22], as well as a personal communication by M. Barbacid and S. Ortega in support of our proposal) that more cells undergo replication in Cdk4R24C knockin mice than in wild-type mice.

We also wondered whether beta cell hyperplasia could cause sustained hypoglycaemia and hyperinsulinaemia in Cdk4R24C knockin mice. As noted, these mice showed no signs of fasting hypoglycaemia or hyperinsulinaemia. The Cdk4R24C knockin phenotype has tightly controlled in vivo insulin secretion in response to glucose, since the insulin secretion peak in the IGTTs was higher and faster to materialise, and paralleled by a lower glycaemic peak in response to an acute intraperitoneal glucose stimulus, without leading to “bounced” hypoglycaemia. As regards the other metabolic parameters analysed (glucose oxidation, utilisation, and proinsulin conversion), Cdk4R24C islets remained completely normal.

However, in our perifusion studies using islets from Cdk4R24C knockin or wild-type mice, the burst of insulin secretion after exposure to a high glucose concentration was greater in amplitude and longer-lasting in R24C islets than that in wild-type controls. Interestingly, Cdk4R24C knockin mice develop a wide spectrum of tumors at later ages, among them endocrine tumors (89% of the adenomas found in Cdk4R24C pancreases correspond to insulin-producing beta cells [23]). This could explain the larger amplitude and width of the insulin secretion peak found in Cdk4R24C islets in perifusion experiments. However, in our animal facility the Cdk4R24C colony has not been found to undergo hypoglycaemia at advanced ages. It is possible, therefore, that the ex vivo perifusion experiments do not completely reflect the in vivo scenario, in which insulin is metabolised in various tissues, especially the liver, thereby maintaining glucose homeostasis. Importantly, although the R24C mutation could confer an extreme phenotype on Cdk4R24C knockin mice (leading to tumor formation late in life), other milder ways of regulating Cdk4 activity might constitute a new approach to increasing beta cell mass. In this context, it is worth noting that Cdk4R24C mice heterozygous for the R24C mutation have a lower incidence of tumor formation than mice homozygous for the mutation.

It was essential to determine whether beta cell replication could be triggered by Cdk4 activation in human pancreatic islets, in order to be able to target Cdk4 and induce specific beta cell replication. Our and other recent observations using viral vectors show the feasibility of expressing certain proteins in the islets [24, 25, 26, 27] without compromising their functionality and viability. We implemented the methodology required to obtain stable expression in islets infected with lentiviruses because this methodology is more efficient and allows the effects of increased replication to be evaluated in the mid and long term [26]. Our results show that Cdk4R24C-infected islets exhibit enhanced proliferation in response to glucose. Glucose has been shown to have mitogenic effects on beta cells [28, 29], and here we report that beta cell replication induced by Cdk4R24C depends on glucose stimulus, probably by changing the phosphorylation status of certain key molecules in the cell cycle and inducing cyclin D expression.

In conclusion, we have shown that Cdk4R24C mice are normoglycaemic, despite exhibiting higher islet insulin content than wild-type littermates, due to a selective beta cell hyperplasia. Moreover, pancreatic islets from Cdk4R24C knockin mice have normal insulin biosynthesis, glucose utilisation and oxidation, and secrete larger amounts of insulin in response to a glucose stimulus. Importantly, human islet cells expressing Cdk4R24C exhibit higher proliferation rates in response to a glucose stimulus than LacZ-expressing controls. Taken together, these results suggest that Cdk4 kinase is a key molecule in the regulation of normal beta cell replication, and that Cdk4 could play a key role in future therapeutic strategies for Type 1 diabetes.



This study was supported in part by grants from Instituto de Salud Carlos III, Red de Centros (RCMN) C03/08, Red de Grupos G03/212, Fundación Salud 2000 and a grant from Ministerio de Ciencia y Tecnología (CICYT SAF, ref. 2000/0053). N. Marzo has a pre-doctoral fellowship from the Institut de Investigacions Biomèdiques August Pi i Sunyer. C. Mora holds an advanced post-doctoral fellowship (ref. 10-2000-635) from the Juvenile Diabetes Foundation International. Our thanks go to Marta Julià for technical assistance in islet isolation and to B. Thorens for providing the pHR′-CMV-LacZ vector, env-coding vector and PCMVΔR9 plasmid.


  1. 1.
    Bernard C, Berthault MF, Saulnier C, Ktorza A (1999) Neogenesis vs. apoptosis as main components of pancreatic beta cell mass changes in glucose-infused normal and mildly diabetic adult rats. FASEB J 13:1195–1205PubMedGoogle Scholar
  2. 2.
    Swenne I (1982) The role of glucose in the in vitro regulation of cell cycle kinetics and proliferation of fetal pancreatic β-cells. Diabetes 31:754–760PubMedGoogle Scholar
  3. 3.
    Pines J, Hunter T (1995) Cyclin dependent kinases: an embarrassment of riches? In: Hames BD, Glover DM (eds) Frontiers in molecular biology. Molecular immunology. Oxford University Press, Oxford, pp 144–176Google Scholar
  4. 4.
    Rane SG, Dubus P, Mettus RV et al. (1999) Loss of Cdk-4 expression causes insulin-deficient diabetes and Cdk-4 activation results in β-islet cell hyperplasia. Nat Genet 22:44–52CrossRefPubMedGoogle Scholar
  5. 5.
    Morgan DO (1995) Principles of CDK regulation. Nature 374:131–134PubMedGoogle Scholar
  6. 6.
    Dunlop M, Muggli E, Clark E (1996) Association of cyclin-cependent kinase-4 and cyclin D1 in neonatal βcells after mitogenic stimulation by lysophosphatidic acid. Biochem Biophys Res Commun 218:132–136CrossRefPubMedGoogle Scholar
  7. 7.
    Tsutsui T, Hesabi B, Moons DS et al. (1999) Targeted disruption of CDK4 delays cell cycle entry with enhanced p27kip1 activity. Mol Cell Biol 19:7011–7019PubMedGoogle Scholar
  8. 8.
    Kaneto H, Kajimoto Y, Fujitani Y et al. (1999) Oxidative stress induces p21 expression in pancreatic islet cells: possible implication in beta-cell dysfunction. Diabetologia 42:1093–1097CrossRefPubMedGoogle Scholar
  9. 9.
    Wölfel T, Hauer M, Schneider J et al. (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284PubMedGoogle Scholar
  10. 10.
    Selawry HP, Mui MM, Paul RD, Distasio JA (1984) Improved allograft survival using highly enriched populations of rat islets. Transplantation 37:202–205PubMedGoogle Scholar
  11. 11.
    Fernández-Alvarez J, Hillaire-Buys D, Loubatieres-Mariani MM, Gomis R, Petit P (2001) P2 receptor agonists stimulate insulin release from human pancreatic islets. Pancreas 22:69–71PubMedGoogle Scholar
  12. 12.
    Dupraz P, Rinsch C, Pralong WF et al. (1999) Lentivirus-mediated Bcl-2 expression in betaTc-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion. Gene Ther 6:1160–1169CrossRefPubMedGoogle Scholar
  13. 13.
    Conget S, Sarri Y, Novials A, Casamitjana R, Vives M, Gomis R (1994) Functional properties of isolated human pancreatic islets: beneficial effects of culture and exposure to high glucose concentrations. Diabetes Metab 20:99–107Google Scholar
  14. 14.
    Scharp DW, Lacy PE, Santiago JV, McCullough CS, Weide LG, Falqui L (1990) Insulin independence after islet transplantation into type I diabetic patients. Diabetes 39:515–518Google Scholar
  15. 15.
    Shapiro AM, Lakey JR, Ryan EA et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230–238PubMedGoogle Scholar
  16. 16.
    Bonner-Weir S, Smith FE (1994) Islets of Langerhans morphology and its implications. In: Kahn CR, Weir GC (eds) Joslin’s diabetes mellitus. Lea & Febiger, Philadelphia, pp 15–28Google Scholar
  17. 17.
    Mellert J, Hering BJ, Hopt TU et al. (1992) Effect of local and systemic macrophage blocking on engraftment of allogeneic porcine islet. Transplant Proc 24:2847PubMedGoogle Scholar
  18. 18.
    Soria B, Roche E, Berná G, León-Quinto T, Reig JA, Martin F (2000) Insulin-secreting cells derived from embryonic stem cells normalize glycaemia in streptozotocin-induced diabetic mice. Diabetes 49:157–162PubMedGoogle Scholar
  19. 19.
    Fleischer N, Chen C, Surana M et al. (1998) Functional analysis of a conditionally transformed pancreatic β-cell line. Diabetes 47:1419–1425Google Scholar
  20. 20.
    Serrano M, Gómez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D (1995) Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 267:250–251Google Scholar
  21. 21.
    Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707PubMedGoogle Scholar
  22. 22.
    Martín J, Hunt SL, Dubus P et al. (2003) Genetic rescue of Cdk4 null mice restores pancreatic β-cell proliferation but not homeostatic cell number. Oncogene 22:5261–5269CrossRefPubMedGoogle Scholar
  23. 23.
    Sotillo R, Dubus P, Martín J et al. (2001) Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 20:6637–6647CrossRefPubMedGoogle Scholar
  24. 24.
    Becker TC, BeltrandelRio H, Noel RJ, Johnson JH, Newgard CB (1994) Overexpression of hexokinase I in isolated islets of Langerhans via recombinant adenovirus. J Biol Chem 269:21234–21238PubMedGoogle Scholar
  25. 25.
    Naldini L, Blömer U, Gallay P et al. (1996) In vivo gene delivery and stable transduction of non dividing cells by a lentiviral vector. Science 272:263–267PubMedGoogle Scholar
  26. 26.
    Naldini L, Blömer U, Gage FH, Trono D, Verma MI (1996) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci 93:11382–11388CrossRefPubMedGoogle Scholar
  27. 27.
    Novials A, Jiménez-Chillarón JC, Franco C, Casamitjana R, Gomis R, Gómez-Foix AM (1998) Reduction of islet amylin expression and basal secretion by adenovirus-mediated delivery of amylin antisense cDNA. Pancreas 17:182–186PubMedGoogle Scholar
  28. 28.
    Del Zotto H, Gomez Dumm CL, Drago S, Fortino A, Luna GC, Gagliardino JJ (2002) Mechanisms involved in the beta cell mass increase induced by chronic sucrose feeding to normal rats. J Endocrinol 174:225–231PubMedGoogle Scholar
  29. 29.
    Trumper A, Trumper K, Horsch D (2002) Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta (INS-1)-cells. J Endocrinol 174:233–246Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • N. Marzo
    • 1
  • C. Mora
    • 1
  • M. E. Fabregat
    • 1
  • J. Martín
    • 2
  • E. F. Usac
    • 1
  • C. Franco
    • 1
  • M. Barbacid
    • 2
  • R. Gomis
    • 1
  1. 1.Endocrinology and Nutrition Unit, Department of Medicine, Clinic Hospital/Institute of Biomedical Research August Pi i Sunyer (IDIBAPS)University of BarcelonaBarcelonaSpain
  2. 2.Molecular Oncology (MB) and Biotechnology (SO) ProgrammeNational Center of Oncologic ResearchMadridSpain

Personalised recommendations